Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Primary and secondary resistance in colorectal cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.05.12
Views: 3777
Rating:

Dr Silvia Marsoni – The Institute for Cancer Research, Candiolo, Italy

Dr Silvia Marsoni, Director of clinical research at The Institute for Cancer Research in Candiolo, talks to ecancer about primary and secondary resistance in colorectal cancer at the European Forum on Oncology in Berlin, May 2012.

 

Dr Marsoni’s project aims to understand how patients respond to EGF therapy and why the majority do not respond to treatment. In order to take this back to the lab, mouse models are used to mimic the immune system of the patient. The data can then be used, again, in the clinic to improve and treatment.

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation